Emerging drugs for major depressive disorder: an update

Bibliography

• Boseley S. June 13 2011. Research into brain disorders under threat as drug firms pull out. In guardian.co.uk. Available from: http://www.guardian.co.uk/science/2011/jun/13/research-brain-disorders-under-threat [Retrieved 2 February 2012]
   Google Scholar
• Collins PY, Patel V, Joestl SS, Grand challenges in global mental health. Nature 2011;475:27-30
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi SJ. Emerging drugs for major depressive disorder. Exp Opin Emerging Drugs 2009;14:1-15
   PubMedGoogle Scholar
• Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007;131:596-610
   PubMed Web of Science ®Google Scholar
• Lucas G, Rymar VV, Sadikot AF, Debonnel G. Further evidence for an antidepressant potential of the selective sigma1 agonist SA 4503: electrophysiological, morphological and behavioural studies. Int J Neuropsychopharmacol 2008;11:485-95
   PubMed Web of Science ®Google Scholar
• Tottori K, Miwa T, Uwahodo Y, Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 2001;41:976-88
   PubMed Web of Science ®Google Scholar
• Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008;3:e2558
   PubMed Web of Science ®Google Scholar
• Villard V, Meunier J, Chevallier N, Maurice T. Pharmacological interaction with the sigma1 (tau1)-receptor in the acute behavioral effects of antidepressants. J Pharmacol Sci 2011;115:279-92
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Ishiwata K, Ishii K, High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 2007;62:878-83
   PubMed Web of Science ®Google Scholar
• Nakano M, Osada K, Misonoo A, Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells. Life Sci 2010;86:309-14
   PubMed Web of Science ®Google Scholar
• Urani A, Roman FJ, Phan VL, The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001;298:1269-79
   PubMed Web of Science ®Google Scholar
• De Wied D, Diamant M, Fodor M. Central nervous system effects of the neurohypophyseal hormones and related peptides. Front Neuroendocrinol 1993;14:251-302
   PubMed Web of Science ®Google Scholar
• van Londen L, Goekoop JG, van Kempen GM, Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacol 1997;17:284-92
   PubMed Web of Science ®Google Scholar
• van Londen L, Kerkhof GA, van den Berg F, Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry 1998;43:196-204
   PubMed Web of Science ®Google Scholar
• Racagni G, Riva MA, Molteni R, Mode of action of agomelatine: synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry 2011;12:574-87
   PubMed Web of Science ®Google Scholar
• Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009;10:1069-84
   PubMed Web of Science ®Google Scholar
• Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Guidance for Industry. Food and Drug Administration, 1998. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078749.pdf [Last accessed 6 February 2012]
   Google Scholar
• First MB. DSM-5 proposals for mood disorders: a cost-benefit analysis. Curr Opin Psychiatry 2011;24:1-9
   PubMed Web of Science ®Google Scholar
• Laughren TP, Gobburu J, Temple RJ, Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 2011;72:1166-73
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2011;http://dx.doi.org/10.1016/j.euroneuro.2011.11.008 [Epub ahead of print]
   Web of Science ®Google Scholar
• Alvarez E, Perez V, Dragheim M, A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2011; DOI: 10.1017/S1461145711001027 [Epub ahead of print]
   Google Scholar
• Aan het Rot M, Collins KA, Murrough JW, Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-45
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802
   PubMed Web of Science ®Google Scholar
• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects with Major Depressive Disorder. GlaxoSmithKline, 2010. Available from: http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?compound=orvepitant&studyType=All&phase=All&population=All&marketing=All [Last accessed 23 January 2012]
   Google Scholar
• Dauden E, Griffiths CE, Ortonne JP, Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009;23:1374-82
   PubMed Web of Science ®Google Scholar
• Kekow J, Moots R, Khandker R, Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011;50:401-9
   PubMed Web of Science ®Google Scholar
• Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010;67:432-8
   PubMed Web of Science ®Google Scholar
• Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 2010;35:2479-88
   PubMed Web of Science ®Google Scholar
• Nichols AI, Focht K, Jiang Q, Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011;31:155-67
   PubMed Web of Science ®Google Scholar
• Fabre LF, Brown CS, Smith LC, Derogatis LR. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. J Sex Med 2011;8:1411-19
   PubMed Web of Science ®Google Scholar
• Fabre LF, Smith LC, DeRogatis LR. Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain–a post hoc analysis. J Sex Med 2011;8:2569-81
   PubMed Web of Science ®Google Scholar
• Fabre LF, Clayton AH, Smith LC, The effect of gepirone-er in the treatment of sexual dysfunction in depressed men. J Sex Med 2012;9:821-9
   PubMed Web of Science ®Google Scholar
• Tran P, Skolnick P, Czobor P, Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2012;46:64-71
   PubMed Web of Science ®Google Scholar
• Learned S, Graff O, Roychowdhury S, Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J Psychopharmacol 2011; doi: 10.1177/0269881111424931 [Epub ahead of print]
   PubMedGoogle Scholar
• Dube S, Dellva MA, Jones M, A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res 2010;44:356-63
   PubMed Web of Science ®Google Scholar
• Pangallo B, Dellva MA, D'Souza DN, A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 2011;45:748-55
   PubMed Web of Science ®Google Scholar
• Gandey A. Pramipexole lawsuits a wake-up call for prescribers. 2010. Available from: www.medscape.com/viewarticle/734153 [Last accessed 23 January 2012]
   Google Scholar
• Coric V, Feldman HH, Oren DA, Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 2010;27:417-25
   PubMed Web of Science ®Google Scholar
• Blasey CM, Block TS, Belanoff JK, Roe RL. Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol 2011;31:436-40
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Vythilingam M, Murrough JW, A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 2011;21:221-9
   PubMed Web of Science ®Google Scholar
• Wade AG, Crawford GM, Nemeroff CB, Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. Psychol Med 2011;41:2089-97
   PubMed Web of Science ®Google Scholar
• Binneman B, Feltner D, Kolluri S, A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008;165:617-20
   PubMed Web of Science ®Google Scholar
• Keller M, Montgomery S, Ball W, Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216-23
   PubMed Web of Science ®Google Scholar